# ELTP earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ELTP) · [Earnings tab](https://www.lopjlb.com/stock/ELTP?tab=earnings)

Updated: 2026-08-15T06:26:09

Quarters analyzed: 8

## Cross-quarter narrative

Across eight earnings calls Elite Pharmaceuticals evolved from a high‑growth, cash‑negative FY2024 to a cash‑rich, low‑debt FY2026 with revenue expanding from $56.6 M to $149 M. Early calls highlighted record revenue, strong amphetamine demand and a $70 M FY2025 outlook but flagged working‑capital strain, DEA quota limits and pending facility approvals. By FY2025 Q1‑Q2 the company turned cash‑flow positive, doubled revenue, and began delivering several generic launches while still wrestling with FDA review extensions and opioid litigation. FY2025 Q3‑Q4 emphasized record FY2025 results, accelerated M&A/NASDAQ planning and mounting competitive pricing pressure on new ADHD and opioid generics. FY2026 calls show continued revenue acceleration, margin rebound after one‑time wholesaler fees, and a fortified balance sheet (working capital +106%, debt down 20%). Regulatory constraints persist via DEA quotas and FDA pilot program access, while litigation uncertainty around Purdue‑related patents and aggressive generic competition remain focal risks. The strategic narrative shifts from securing manufacturing capacity and cash to leveraging scale, expanding indirect channels, and pursuing M&A or uplisting options.

## Latest CallCard · Q4

ELTP FY2026: Revenue $149M (+77%), Op Income $49M (+151%), cash $29.8M, debt down 20%; pipeline advancing with OxyContin ER, anticoagulant, anticonvulsant; M&A/NASDAQ options explored.

**Guidance:** vague — No explicit financial guidance provided for FY2027; next report is 10-Q for Q1 FY2027 due August 2026.

**Tone:** mgmt 0.9 · Q&A pressure 0.05 · divergence 0.9

Management highlights record revenue, profit, cash flow, balance sheet strengthening, and strong pipeline progress, expressing confidence in sustained growth and strategic options.

### Demand visibility

Strong visibility for existing portfolio with growing market shares in generic ADHD, opioid, and niche products; new launches add incremental visibility.

Listdex (generic Vyvanse) at ~10% share in growing market; Amphetamine IR 14% share in 6-12% growing market; Amphetamine ER 12% share; Naltrexone 12% share; Phendimetrazine 30% share; recent launches (methadone, codeine combos, methotrexate) and upcoming Ropinirole/ER ($12M market) expand visibility.

### Margins / costs

Margins expanded significantly with operating income up 151% on 77% revenue growth, driven by favorable product mix and scale; direct/indirect shift noted but mix and market conditions more impactful.

Gross margin percentage hit record high; direct sales 44% (higher margin, lower volume) vs indirect 56%; methadone noted as low-margin; product mix and real-time market conditions primary margin drivers.

### Capital allocation

Balance sheet strengthening with cash up 163% to $29.8M, working capital up 106% to $95M, long-term debt down 20% to $4.7M; debt paydown prioritized; warrants expiring next year; M&A/NASDAQ options pursued

## Quarter one-liners

- **2026 Q4:** ELTP FY2026: Revenue $149M (+77%), Op Income $49M (+151%), cash $29.8M, debt down 20%; pipeline advancing with OxyContin ER, anticoagulant, anticonvulsant; M&A/NASDAQ options explored.
- **2026 Q3:** Elite Pharma reported Q3 FY2026 revenue of $31.6M, a 120% YoY rise, strong working‑capital growth and expanding indirect‑channel sales, while noting pricing pressure and pending product launches.
- **2026 Q2:** Elite Pharmaceuticals reports 92% YoY revenue growth to $36.3M in FQ2'26 driven by generic Vyvanse (Lisdex) and Adderall, but margins pressured by competition and one-time fees; balance sheet strengthens with working capital up 63% and debt declining.
- **2025 Q4:** Elite Pharmaceuticals reported record FY2025 revenue of $84M (+52%) and operating income of $19.6M (+82%), driven by Lisdexamfetamine launch and strong Amphetamine IR/ER share; balance sheet strengthened with working capital up 41% to $45.9M and debt decreasing; M&A is primary strategic priority wit
- **2025 Q3:** Elite Pharmaceuticals reports Q3 revenue dip due to holiday shipment delays but highlights record January shipments, Vyvanse launch momentum, new packaging facility approval, and accelerated M&A/NASDAQ plans.
- **2025 Q2:** Elite Pharmaceuticals reports Q2 FY2025 revenue of $18.9M (+33% YoY), operating income $3.5M (+81% YoY), positive cash flow $4.6M YTD, strong pipeline with new launches (methotrexate, codeine/APAP, hydrocodone/APAP, oxycodone/APAP, methadone) and facility expansion.
- **2025 Q1:** Elite Pharma Q1 FY2025 saw revenue double to $18.8M, operating income rise to $3.9M, positive cash flow and a pipeline of approved ANDAs with multiple product launches slated, while a new 34k‑sq‑ft facility awaits final DEA/FDA approvals.
- **2024 Q4:** Elite Pharma posted record $56.6M revenue and $10.8M operating income in FY2024, highlighted a successful Elite label launch, strong amphetamine demand, and a $70M revenue outlook for FY2025 despite working‑capital strain.

## Theme arcs

- **Revenue Growth** (improving): Revenue rose from $56.6M (FY2024) to $149M (FY2026)
- **Margin Pressure** (deteriorating): Competitive pricing and one‑time fees squeezed margins in FY2025‑FY2026
- **Regulatory Constraints** (stable): DEA quota limits and pending approvals cited in every call
- **Working Capital Strength** (improving): From negative cash flow FY2024 to $29.8M cash and $95M working capital FY2026
- **M&A & NASDAQ Strategy** (new): First mentioned FY2025 Q3, intensified through FY2026
- **Product Launch Execution** (stable): Mixed outcomes: many launches delivered, some delayed or still on track
- **Legal/Litigation Risk** (stable): Patent litigation with Purdue recurring across calls
- **Competitive Pricing** (deteriorating): Increasing number of generic competitors eroding prices
- **Guidance Uncertainty** (stable): Uncertainty scores remained moderate (0.30‑0.60)
- **Management Tone** (stable): Management tone stayed high (0.80‑0.90) despite challenges

## Fear persistence

- **Regulatory** [recurring]: DEA quota limits and pending approvals appear in every call
- **Financial** [resolved]: Early working‑capital strain disappeared as cash and working capital grew
- **Execution** [resolved]: Initial DEA approval delays cleared by FY2025 Q3
- **Product reliance on amphetamines** [recurring]: Continues to be a vulnerability due to quota constraints
- **Legal/Patent litigation** [recurring]: Purdue‑related litigation persists through FY2026
- **Competitive pricing** [recurring]: Increasing generic competition drives price erosion
- **M&A uncertainty** [new]: First highlighted FY2025 Q3 and remains ongoing
- **Compliance costs** [new]: G&A rise from multi‑state registrations noted FY2026 Q2
- **Quota limitation** [recurring]: DEA quota constraints repeatedly cited as sales cap
- **Supply chain cost** [new]: Wholesaler fees and supply chain costs noted FY2026 Q3

## Guidance path

2024 Q4:raised → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q2:vague → 2026 Q3:vague → 2026 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ELTP`